Suppr超能文献

减瘤手术及腹腔内热灌注化疗治疗卵巢癌术后胃排空延迟的危险因素

Risk factors for postoperative delayed gastric emptying in ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

作者信息

Cui Guang-Xia, Wang Zi-Jun, Zhao Jin, Gong Ping, Zhao Shuai-Hong, Wang Xiao-Xue, Bai Wen-Pei, Li Yan

机构信息

Department of Gynecology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Department of Peritoneal Caner Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

出版信息

World J Clin Cases. 2021 Jun 26;9(18):4644-4653. doi: 10.12998/wjcc.v9.i18.4644.

Abstract

BACKGROUND

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has shown promising results in improving the survival of ovarian cancer patients. Although the safety profiles of CRS-HIPEC exist, more attention should be paid to gastrointestinal complications, as the procedure involves a considerable proportion of bowel resection and anastomosis.

AIM

To identify the risk factors for delayed gastric emptying in ovarian cancer treated with CRS-HIPEC.

METHODS

A cross-sectional study was conducted. According to the inclusion and exclusion criteria, we retrospectively analyzed 77 patients admitted between March 2014 and April 2018 with advanced and recurrent ovarian cancer treated with CRS-HIPEC in Beijing Shijitan Hospital of Capital Medical University. Risk factors for delayed gastric emptying were analyzed using univariate analysis. All of the statistically significant variables in the univariate analysis were entered into the multivariable logistic regression model to determine factors independently associated with delayed gastric emptying.

RESULTS

Among the 77 included patients, 36.4% (28/77) had delayed gastric emptying after CRS-HIPEC. The median age and body mass index of all patients were 59 years and 22.83 kg/m, respectively. Preoperative chemotherapy was administered in 55 patients (71%). Sixty-two patients (81%) had a history of at least one previous pelvic surgery. The median operation time and intraoperative hemorrhage volume were 630 min and 600 mL, respectively. Omentectomy was performed in 32 cases of primary ovarian cancer and 24 cases of recurrence. The median peritoneal cancer index was 16. The risk factors for delayed gastric emptying from the univariate analysis were body mass index < 23 kg/m ( = 5.059, = 0.025), history of pelvic surgery ( = 4.498, = 0.034), history of chemotherapy ( = 4.334, = 0.037), operation time ≥ 7 h ( = 4.827, = 0.047), and intraoperative hemorrhage ≥ 800 mL ( = 7.112, = 0.008). Multivariable analysis revealed that age ≥ 70 years (HR = 7.127; 95%CI 1.122-45.264; = 0.037) and intraoperative hemorrhage ≥ 800 mL (HR = 3.416; 95%CI 1.067-10.939; = 0.039) were independently associated with postoperative delayed gastric emptying after CRS-HIPEC.

CONCLUSION

Postoperative gastrointestinal management, including prolonged nasogastric intubation, should be promoted for patients over 70 years or those with intraoperative bleeding exceeding 800 mL.

摘要

背景

细胞减灭术和腹腔热灌注化疗(CRS-HIPEC)在提高卵巢癌患者生存率方面已显示出有前景的结果。尽管CRS-HIPEC存在安全性概况,但由于该手术涉及相当比例的肠切除和吻合,应更多关注胃肠道并发症。

目的

确定接受CRS-HIPEC治疗的卵巢癌患者胃排空延迟的危险因素。

方法

进行了一项横断面研究。根据纳入和排除标准,我们回顾性分析了2014年3月至2018年4月间在北京首都医科大学附属北京世纪坛医院接受CRS-HIPEC治疗的77例晚期和复发性卵巢癌患者。采用单因素分析胃排空延迟的危险因素。单因素分析中所有具有统计学意义的变量都被纳入多变量逻辑回归模型,以确定与胃排空延迟独立相关的因素。

结果

在纳入的77例患者中,36.4%(28/77)在CRS-HIPEC后出现胃排空延迟。所有患者的中位年龄和体重指数分别为59岁和22.83kg/m²。55例患者(71%)接受了术前化疗。62例患者(81%)有至少一次既往盆腔手术史。中位手术时间和术中出血量分别为630分钟和600毫升。32例原发性卵巢癌和24例复发病例进行了大网膜切除术。中位腹膜癌指数为16。单因素分析中胃排空延迟的危险因素为体重指数<23kg/m²(χ²=5.059,P=0.025)、盆腔手术史(χ²=4.498,P=0.034)、化疗史(χ²=4.334,P=0.037)、手术时间≥7小时(χ²=4.827,P=0.047)和术中出血≥800毫升(χ²=7.112,P=0.008)。多变量分析显示,年龄≥70岁(HR=7.127;95%CI 1.122-45.264;P=0.037)和术中出血≥800毫升(HR=3.416;95%CI 1.067-10.939;P=0.039)与CRS-HIPEC术后胃排空延迟独立相关。

结论

对于70岁以上或术中出血超过800毫升的患者,应加强术后胃肠道管理,包括延长鼻胃管插管时间。

相似文献

4
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Eur J Cancer. 2020 Mar;127:76-95. doi: 10.1016/j.ejca.2019.10.034. Epub 2020 Jan 24.
6
10
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol. 2016 May;23(5):1609-17. doi: 10.1245/s10434-015-5012-3. Epub 2015 Dec 17.

本文引用的文献

1
Epithelial ovarian cancer.
Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.
3
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.
6
Epidemiology of epithelial ovarian cancer.
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. Epub 2016 Oct 3.
9
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
10
Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Ann Surg Oncol. 2015 May;22(5):1570-5. doi: 10.1245/s10434-014-4157-9. Epub 2014 Nov 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验